The much-hyped weight-loss and semaglutide therapy market has hit an early speed bump, with industry estimates pegging the value of excess stock in the trade channel at around Rs 100 crore, according to sources cited by the Times of India. Stockists and wholesalers are currently holding 50-60 days of inventory—well above the normal 30-45 days—and have stopped fresh procurement from pharmaceutical companies until existing stocks are cleared.
The Slowdown After the Surge
The strong growth witnessed in the Rs 2,000-crore obesity therapy market in April lost steam in May, according to the latest data from market research firm Pharmarack. Month-on-month value growth slowed to 6% and unit growth to 12% in May, compared to a surge of 50% in value terms and 88% in volumes in April. The initial boom followed a flood of cheaper generic semaglutide launches after the drug went off-patent on March 20.
Inventory Overhang and Procurement Pause
Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists (AIOCD), which represents over 12 lakh chemists and stockists across the country, said: “There is significant inventory overhang in the market, with stockists and wholesalers currently holding nearly 50-60 days of GLP-1 (semaglutide) stock. Sales in May were slower than anticipated, leading channel partners to pause fresh purchases from manufacturers until existing stocks are liquidated. The inventory in the trade channel could be worth close to Rs 100 crore.”
Generic Entrants and Competitive Landscape
The patent expiry on March 20 triggered a rapid influx of generic semaglutide brands from players including Torrent, Sun Pharma, and Dr Reddy's. However, the moderation in sales after the initial surge has raised fears of inventory-led losses for these manufacturers. Meanwhile, the weight-loss shot Mounjaro (tirzepatide), marketed by Eli Lilly, continued to be the largest selling therapy in the pharma market during May, with sales up by 12% at Rs 136 crore, as per Pharmarack data.
Regulatory Impact on Sales
Industry executives cited by the Times of India said the moderation in sales may partly be linked to government advisories and prescribing restrictions around GLP-1 therapies. The guidelines announced in April stipulate that these medicines should be prescribed only by qualified specialists, potentially dampening demand from general practitioners.
Broader Pharma Market Context
Overall, the Rs 2.5 lakh crore organised pharma retail grew nearly 11% during May, buoyed largely by chronic therapies. Both semaglutide and tirzepatide belong to the GLP-1 (glucagon-like peptide-1) receptor agonists class, used for the management of type 2 diabetes and obesity. The inventory overhang in the semaglutide segment contrasts with the broader market's steady growth, highlighting the risks of rapid generic entry without matching demand.
The table below summarises the key metrics from the source:
| Metric | April | May |
|---|---|---|
| Month-on-month value growth | 50% | 6% |
| Month-on-month unit growth | 88% | 12% |
| Inventory level (days) | Normal (30-45) | 50-60 |
| Excess stock value | - | ~Rs 100 crore |
For manufacturing executives, the situation underscores the importance of aligning production capacity with real-time demand signals. The sudden transition from supply shortage to inventory glut can strain working capital and supply chain relationships. Pharmaceutical plant managers may need to review production schedules and buffer stocks in light of the current channel freeze. The overhang also raises questions about the sustainability of the rapid generic launch strategy without robust demand forecasting, especially in a market subject to regulatory shifts.
Sources:
